Shuchi Nahar's Weekend Blog!

Media Sector - Opportunity ! Shuchi.P.Nahar To understand the sector ,here is my article to understanding in depth media sector Part1:  https://myweekendspot.blogspot.com/2020/03/understanding-media-sector.html Part2: https://myweekendspot.blogspot.com/2020/03/understanding-media-sector-part-2.html Digital communication was anyway becoming the way of life, a reality that has accelerated amid the COVID19 crisis. Amid the lockdown in India which is our primary market, people have been spending more time on digital media. As we enter 2020, it’s clear that the growth of  video streaming  will continue to explode. In fact, in most recent Digital Media Trends Survey, more respondents indicated that they have at least one streaming video subscription (69%) than possess a traditional pay-TV subscription (65%). At the same time, an all-out streaming war is underway, with virtually every media company looking to establish direct relationships with consumers. It now appears that

“Practitioners’ Insights: Understanding Pharma” Shuchi.P.Nahar India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50% of global demand for various vaccines,  40% of generic demand in the US and 25 % of all medicine in UK. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 % of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are by Indian pharmaceutical firms. The global pharmaceutical market is expected to exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. The key drivers of growth will continue to be the United States and emerging markets with 4−7% and 5–8% compound annual growth, respectively. The global outlook for medicine use and spendi

Important Segments to track growth for Pharma Companies Shuchi.P.Nahar Investments in the global pharmaceuticals sector to increase to over $1,400 billion over the next three years, driven by a number of new medicines. With healthy R&D spending going forward, the Contract Research and Manufacturing (CRAMS) segment offers growth opportunities to Indian companies .  Change in regulations around generic approvals will help Indian companies to increase penetration in Chinese markets, which will improve margin expansion.  What are CRAMS ?  CRAMS is defined as the process of outsourcing research services/ product manufacturing activities to organizations which can provide the service at a low cost. CRAMS basically consists of the following two activities: contract research and contract manufacturing. CRAMS is mainly used in the Pharmaceutical and Biotechnology sectors that require extensive R&D and large-scale manufacturing facilities. It is expected that the demand for c

Growth Outlook of Pharmaceutical Sector! Key Points to Know. SHUCHI.P.NAHAR The Indian market is impossible to ignore, given its economic prospects. Foreign companies view India as a potential significant contributor of future sales and are ramping up their investments in the country accordingly. India’s domestic market looks promising for global pharma looking to launch new products.  The country’s growing capabilities in contract manufacturing, R&D and clinical trials also make it a preferred outsourcing partner for global pharma at every stage of the value chain. So what strategy should foreign pharmaceutical companies eager to enter the country or expand their existing operations adopt?   The growth trajectory for the Indian pharmaceutical industry is likely to remain at 10-13 percent in 2020-21 despite challenges, according to rating agency ICRA. The expected growth in the next financial year is on the back of healthy demand from the domestic market given incre